Not provided
Not provided
Not provided
Not provided
Not provided
Feasibility pilot was completed
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active N-acetylcysteine and Active Delta-9-THC | Experimental |
| |
| Placebo and Active Delta-9-THC | Placebo Comparator |
| |
| Active N-acetylcysteine and Placebo | Experimental |
| |
| Placebo and Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Delta-9-THC | Drug | Active Delta-9-THC (0.036mg/Kg) given intravenously. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS | -30 minutes from administration of THC |
| Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS | +15 minutes from administration of THC |
| Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS | +90 minutes from administration of THC |
| Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS | +240 minutes from administration of THC |
| Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS | -60 minutes from administration of THC |
| Measure | Description | Time Frame |
|---|---|---|
| Clinician Administered Dissociative Symptoms Scale (CADSS) | Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-reported items and 8 clinician-rated items. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment. | -60min, -30min, +15min, +90min, +240min from administration of THC |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohini Ranganathan, MD | Yale University Medical School | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VA Connecticut Healthcare System | West Haven | Connecticut | 06516 | United States |
Not provided
| ID | Term |
|---|---|
| D002189 | Marijuana Abuse |
| D011618 | Psychotic Disorders |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D013759 | Dronabinol |
| D000111 | Acetylcysteine |
| ID | Term |
|---|---|
| D002186 | Cannabinoids |
| D013729 | Terpenes |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| N-acetylcysteine | Drug | A pill given orally. |
|
| Placebo | Drug | Placebo (about a quarter spoon of alcohol with no THC) given intravenously. |
|
| Placebo | Drug | Placebo "sugar" pill given orally with no N-acetylcysteine. |
|
| Visual Analog Scale (VAS) | Feeling states associated with cannabis intoxication will be measured using a self-reported visual analog scale of feeling states associated with cannabis effects (ex: "high," "calm," "anxious"). Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11mm line. These data will be captured to validate that the experiment is relevant to cannabis effects. | -60min, -30min, +15min, +90min, +240min from administration of THC |
| Cognitive Test Battery | Several computer tasks will be administered in order to evaluate the effects of cannabis on recognition memory, working memory, and attention. The battery consists of four computer tasks that lasts no longer than 20 minutes in total. | +20min from administration of THC |
| Hopkins Verbal Learning Test (HVLT) | The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials and a different version of the HVLT will be administered on each test day. | +20min from administration of THC |
| Psychotomimetic States Inventory (PSI) | The PSI is a measure of drug induced psychotomimetic states. This self-reported scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC. | -60min, -30min, +240min from administration of THC |
| D003545 |
| Cysteine |
| D000603 | Amino Acids, Sulfur |
| D013457 | Sulfur Compounds |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |